SequelSEC

MARAVAI LIFESCIENCES HOLDINGS, INC. MRVI

Pharmaceutical Preparations · CIK 0001823239 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$185.74M
Fiscal year ended 2025-12-31
Operating income
-$215.27M
Fiscal year ended 2025-12-31
Free cash flow
-$70.72M
Fiscal year ended 2025-12-31

MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) reported revenue of $185.74M and net income of -$130.77M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from MARAVAI LIFESCIENCES HOLDINGS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MARAVAI LIFESCIENCES HOLDINGS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue$185.74M$259.18M$288.94M$883.00M$799.24M$284.10M$143.14M
Cost of revenue$151.75M$150.88M$148.74M$168.96M$140.56M$79.65M$66.85M
Gross profit$33.99M$108.31M$140.20M$714.04M$658.68M$204.45M$76.29M
Operating income-$215.27M-$235.62M-$31.65M$574.22M$554.64M$119.90M$23.99M
Net income-$130.77M-$144.85M-$119.03M$220.20M$182.04M$88.97M-$4.47M
Research & development$17.40M$19.22M$17.28M$18.37M$15.22M$9.30M$3.63M
Weighted-average diluted sharesshares 144.36Mshares 137.91Mshares 131.92Mshares 255.32Mshares 257.80Mshares 28.91Mshares 253.92M
Pretax income-$234.97M-$261.48M$617.74M$551.47M$530.76M$81.70M-$5.85M
Income tax expense-$4.21M-$1.86M$756.11M$60.81M$61.52M$2.88M-$652.00K
Diluted EPS$-0.90$-1.05$-0.90$1.67$1.56$2.36$-0.03
Selling, general & administrative$145.12M$161.77M$151.39M$129.26M$100.06M$94.24M$48.35M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MARAVAI LIFESCIENCES HOLDINGS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$216.89M$322.40M$574.96M$632.14MUnavailableUnavailableUnavailable
Total assets$770.58M$1.01B$1.49B$2.28B$1.92B$1.27BUnavailable
Current assets$296.25M$429.15M$699.91M$847.90M$740.04M$331.60MUnavailable
Total liabilities$397.87M$431.04M$697.57M$1.38B$1.37B$1.12BUnavailable
Current liabilities$44.92M$56.97M$87.47M$110.14M$93.78M$130.78MUnavailable
Total equity incl. NCI$372.71M$577.21M$789.88M$905.24M$545.36M$154.75M$144.63M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$40.50M$50.08M$51.40M$43.15M$51.56M$33.30MUnavailable
Accounts receivable$25.50M$38.52M$54.60M$138.62M$117.51M$51.02MUnavailable
Goodwill$129.43M$159.88M$326.03M$283.67M$152.77M$224.28MUnavailable
Long-term debt$286.33M$290.49M$518.71M$522.00M$524.59M$528.61MUnavailable
Accounts payable$2.91M$11.96MUnavailable$5.99M$8.15M$8.17MUnavailable

Cash flow

MARAVAI LIFESCIENCES HOLDINGS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$57.57M$7.46M$126.22M$535.98M$368.57M$152.19M$24.12M
Capital expenditures$13.15M$29.66M$65.55M$17.09M$14.85M$25.41M$17.15M
Investing cash flow-$31.40M-$24.32M-$122.31M-$267.61M$105.66M$6.07M-$17.15M
Financing cash flow-$16.50M-$235.71M-$61.09M-$187.50M-$159.05M$53.21M-$4.17M
Net change in cash-$105.51M-$252.56M-$57.18M$80.87M$315.09M$211.48M$2.83M
Stock-based compensation$30.17M$49.42M$34.59M$18.67M$10.46M$24.63M$1.68M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable$0$0$33.66M$0
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

MARAVAI LIFESCIENCES HOLDINGS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flow-$70.72M-$22.19M$60.67M$518.89M$353.72M$126.78M$6.97M
Gross margin18.3%41.8%48.5%80.9%82.4%72.0%53.3%
Operating margin-115.9%-90.9%-11.0%65.0%69.4%42.2%16.8%
FCF margin-38.1%-8.6%21.0%58.8%44.3%44.6%4.9%
SBC / revenue16.2%19.1%12.0%2.1%1.3%8.7%1.2%
Current ratio6.60x7.53x8.00x7.70x7.89x2.54xUnavailable
Revenue YoY growth-28.3%-10.3%-67.3%10.5%181.3%98.5%Unavailable
Net margin-70.4%-55.9%-41.2%24.9%22.8%31.3%-3.1%
R&D / revenue9.4%7.4%6.0%2.1%1.9%3.3%2.5%
CapEx / revenue7.1%11.4%22.7%1.9%1.9%8.9%12.0%
Long-term debt / equity0.77xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailable122.4%11.0%11.6%3.5%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MRVI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-08View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.